华兰疫苗8月27日获融资买入977.95万元，融资余额1.22亿元

Core Viewpoint - Hualan Vaccine experienced a decline of 4.21% in stock price on August 27, with a trading volume of 107 million yuan, indicating market volatility and investor sentiment concerns [1] Financing Summary - On August 27, Hualan Vaccine had a financing buy-in amount of 9.7795 million yuan and a financing repayment of 11.5420 million yuan, resulting in a net financing outflow of 1.7624 million yuan [1] - The total financing and securities lending balance for Hualan Vaccine reached 123 million yuan, with the financing balance accounting for 1.12% of the circulating market value, indicating a high level of financing activity [1] - The company’s financing balance of 122 million yuan is above the 70th percentile of the past year, suggesting strong investor interest [1] Securities Lending Summary - On August 27, Hualan Vaccine repaid 400 shares in securities lending and sold 6,200 shares, with a selling amount of 113,000 yuan based on the closing price [1] - The securities lending balance stood at 456,400 yuan, with a remaining quantity of 25,000 shares, which is above the 60th percentile of the past year, indicating significant short-selling activity [1] Company Overview - Hualan Biological Vaccine Co., Ltd. is located in Xinxiang City, Henan Province, and was established on November 9, 2005, with its stock listed on February 18, 2022 [1] - The company primarily focuses on the research, production, and sales of human vaccines, with vaccine products accounting for 98.11% of its main business revenue [1] Financial Performance - For the first half of 2025, Hualan Vaccine reported an operating income of 59.9618 million yuan, representing a year-on-year growth of 68.77%, while the net profit attributable to shareholders decreased by 17.71% to 20.7972 million yuan [2] - Since its A-share listing, Hualan Vaccine has distributed a total of 680 million yuan in dividends, with 600 million yuan distributed over the past three years [2] Shareholder Structure - As of July 31, 2025, the number of Hualan Vaccine shareholders increased by 12.60% to 19,000, while the average circulating shares per person decreased by 11.19% to 7,454 shares [2] - Notable institutional holdings include the third-largest shareholder, China Merchants Guozhen Biomedicine Index A, holding 2.5351 million shares, a decrease of 115,100 shares from the previous period [2]